Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022
Hannah G. Rosenblum(National Center for Immunization and Respiratory Diseases), Evelyn Twentyman(Synaptic Research (United States)), Oliver Brooks, Ruth Link‐Gelles(Centers for Disease Control and Prevention), Katherine E. Fleming-Dutra(Centers for Disease Control and Prevention), Sara E. Oliver(Centers for Disease Control and Prevention), Monica Godfrey, Grace M. Lee, Lauren E. Roper(National Center for Immunization and Respiratory Diseases), H. Keipp Talbot(Marshfield Clinic), Tamara Pilishvili(Centers for Disease Control and Prevention), Megan J. Wallace(Hudson Institute), Beth P. Bell(Centers for Disease Control and Prevention), Elisha Hall, Sarah Meyer, Matthew F. Daley(Kaiser Permanente), Jennifer Williams, Danielle Moulia(Centers for Disease Control and Prevention)
Cited by 163
Related Papers
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
|MMWR Morbidity and Mortality Weekly Report|2020|2.4k
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602
Surveillance of Vaccination Coverage Among Adult Populations — United States, 2014
|MMWR Surveillance Summaries|2016|510
Surveillance of Vaccination Coverage among Adult Populations — United States, 2015
|MMWR Surveillance Summaries|2017|443
Potential Indirect Effects of the COVID-19 Pandemic on Use of Emergency Departments for Acute Life-Threatening Conditions — United States, January–May 2020
|MMWR Morbidity and Mortality Weekly Report|2020|378